Title : Cotargeting the JAK/STAT signaling pathway and histone deacetylase by ruxolitinib and vorinostat elicits synergistic effects against myeloproliferative neoplasms.

Pub. Date : 2020 Jun

PMID : 31227936






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Cotreatment with ruxolitinib and vorinostat synergistically induced apoptosis, cell cycle arrest and inhibition of the colony-forming capacity of HEL cells by attenuating the JAK/signal transducer and activator of transcription (STAT) and protein kinase-B (AKT) signaling pathways. ruxolitinib protein tyrosine kinase 2 beta Homo sapiens